1 Dividend to Buy, 1 Dividend to Sell (AZN, XOM)

Before you go, we thought you'd like these...
Before you go close icon

This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.

In this edition of the Fool's popular "1 Dividend To Buy, 1 Dividend To Sell" series, David looks at two of the market's most interesting dividend stocks -- one whose prospects he likes and one he thinks investors should avoid. Today, David discusses the potential catalysts and pitfalls for Exxon Mobil and AstraZeneca and declares one of the Big Oil and Big Pharma heavyweights a winner and the other a stock to avoid.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time this article was published David Williamson owns shares of BP. The Motley Fool owns shares of AstraZeneca. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners